MGTXMeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited ret…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal? MeiraGTx Holdings (NasdaqGS:MGTX) announced two senior leadership appointments, adding executives with extensive global pharmaceutical development and manufacturing experience. The company reported a turnaround in second quarter financial performance, shifting from prior net losses to profitability. Management indicated that these leadership changes and financial results could affect MeiraGTx's pipeline progress and commercialization plans. Consider taking a broader look at related... | ||
MeiraGTx Seen Nearing First Commercial Launches as Key Programs Advance, RBC Says MeiraGTx (MGTX) is moving closer to becoming a commercial-stage company, with two potential first-in | MMT Newswires | |
 MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates MeiraGTx (MGTX) delivered earnings and revenue surprises of +538.46% and +20,637.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.69% and -61.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +27.27% and -9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates Pacira (PCRX) delivered earnings and revenue surprises of +14.06% and +1.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates uniQure (QURE) delivered earnings and revenue surprises of -50.62% and -17.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High? The mean of analysts' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. | ||
MMT Newswires | ||